Research & Development

Tokyo New Drug Research Laboratories and Fuji Laboratory are the core centres for Kowa Company Ltd.'s research and development activities in Japan and globally.

At the Tokyo New Drug Research Laboratories we conduct extensive research activities, including searching for new materials and product opportunities and their biological screening, molecular design, and preclinical studies such as biokinetic studies of medicine.

At the Fuji Laboratory we have two research divisions: 1) safety research and drug formulation research, and

2) research on drug delivery systems for efficiently delivering drugs to the target site, development of new dosage forms, development of over-the-counter drugs, and production of investigational agents.

In Europe, Kowa Research Europe, Ltd. take responsibility for the clinical development of Kowa Company Ltd.'s new products.

For more information on our research and development programmes please visit www.kowa.com

Target Areas of R&D

Lifestyle-related diseases

Dyslipidemia

Type 2 Diabetes

Arteriosclerotic disease

Immunity inflammation

Cancer

Inflammatory disease

Skin disease

Sensory organ diseases

Eye disease

Equilibrium and auditory function disorders

Pipeline Last updated: September 2014

Lifestyle-related diseases
Development Code/Generic Name (Administration)

NK-104-PH / Pitavastatin Calcium

NK-104-CR / Pitavastatin Calcium

SK-0403 / Anagliptin

K-877

K-312

K-134

Country/ Region

Japan

Japan

Japan

US

EU

Japan

US

EU

US

Japan

US

Stage

Filed

PII

PIII

PII

PII

PIII

PII

PII

PI

PII

PII

Indications

Familial Hypercholesterolemia (Pediatrics)

Dyslipidemia

Type 2 Diabetes Mellitus (Concomitant use: Glinides, Insulin)

Type 2 Diabetes Mellitus

Dyslipidemia

Dyslipidemia

Arteriosclerotic Disease

Category

HMG-CoA reductase inhibitor

DPP-4 inhibitor

PPAR-α agonist

 

PDE3 inhibitor

Immunity inflammation
Development Code/Generic Name (Administration)

NIK-333, K-333 / Peretinoin

K-912; NC-6300 *

K-103-IP

Country/ Region

Japan

Asia

EU

Japan

US

Stage

PIII

PIII

PI

PI

PIII

Indications

Prevention of Recurrence of Liver Cancer

Solid Tumours

Anti-inflammation and Analgesic

Category

Apoptosis inducer

DNA/RNA Synthesis Inhibitor

COX inhibitor

* Co-developed with SANWA KAGAKU KENKYUSHO CO. LTD.
Sensory organ diseases
Development Code/Generic Name (Administration)

K-115 / Ripasudil hydrochloride hydrate

K-115-R / Ripasudil hydrochloride hydrate

Country/ Region

Japan

Japan

Stage

Launched

PII

Indications

Glaucoma, Ocular Hypertension

Diabetic Retinopathy

Category

Rho kinase inhibitor

Rho kinase inhibitor

Other
Development Code/Generic Name (Administration)

K-163-SZ

Country/ Region

-

Stage

Preparing

Indications

Mental Disorder

Category

 

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X